Sign in

Will Scotton

@drwillscotton.bsky.social
92 followers 152 following 8 posts

• Consultant Neurologist RWT - Movement and Cognitive disorders • Honorary Consultant Queen Elizabeth Hospital Birmingham • NIHR West Midlands Specialty Lead for Neuro-degeneration and Dementia • Honorary post-doctoral researcher, John Hardy Lab UCL

PostsRepliesMedia
Will Scotton @drwillscotton.bsky.social · 27/12/2025
The first GWAS in FTLD-3R Tau a.k.a. Pick's Disease. Please view on LinkedIn.. www.linkedin.com/posts/willia...
linkedin.com
Identification of common variants influencing risk of the three-repeat tauopathy Pick's disease: a genome wide association study. | William Scotton
Half a decade of work.. pleased for all involved that we have pulled it together. The first GWAS in FTLD-3R Tau a.k.a Pick's Disease. Thankyou to all the collaborators involved in the the Pick's Inter...
010
Will Scotton @drwillscotton.bsky.social · 21/10/2025
Come and work with us at RWT! Job advert for senior clinical fellow in the Neurology team www.nhsjobs.com/job/UK/Birmi...
nhsjobs.com
Job vacancy: Portfolio Pathway Fellow - Neurology, The Royal Wolverhampton NHS Trust, Wolverhampton | trac.jobs
010
Will Scotton @drwillscotton.bsky.social · 16/07/2025
Job alert! Come and join an ambitious and growing department with supportive colleagues and plenty of scope for building subspecialty interests.. beautiful surrounding South Staffs and Shropshire countryside and also host the NIHR WM RRDN www.bmj.com/careers/job/...
bmj.com
Consultant in Neurology - Wolverhampton job with The Royal Wolverhampton NHS Trust | 713059
Seeking a Consultant in Neurology joining 10 consultants in the Neurology Directorate covering Wolverhampton, Staffordshire & Shropshire.
020
Will Scotton @drwillscotton.bsky.social · 22/06/2025
movementdisorders.onlinelibrary.wiley.com/doi/full/10....
movementdisorders.onlinelibrary.wiley.com
How Do I Diagnose Multiple System Atrophy—A Videolibrary on Clinical and Imaging Features
Click on the article title to read more.
010
Reposted by Will Scotton
Dementia Researcher @dementiaresearcher.bsky.social · 06/06/2025
Exciting communications role at UCL with Prof Cath Mummery, shaping strategic engagement for the UK Dementia Trials Network. Advance dementia research nationwide! Closing date: 18th June www.dementiaresearcher.nihr.ac.uk/job/uk-dtn-e...
dementiaresearcher.nihr.ac.uk
UK DTN Engagement and Communications Lead
Join Prof Cath Mummery's team at UCL, driving strategic communications for the UK Dementia Trials Network to shape dementia research across the UK.
022
Will Scotton @drwillscotton.bsky.social · 05/06/2025
thelimbus.co.uk/neurology/mp... Abn were already sounding the alarm 5 years ago..
thelimbus.co.uk
MPs sound alarm over neurologist shortage
MPs have urged the Government to urgently tackle a “severe shortage” of neurologists in the NHS, warning that the shortfall is contributing to delays in diagnosis and compromised care for people with ...
010
Will Scotton @drwillscotton.bsky.social · 26/05/2025
12 months of full Immersion. Sad that its over en.m.wikipedia.org/wiki/Aubrey%...
en.m.wikipedia.org
Aubrey–Maturin series - Wikipedia
000
Reposted by Will Scotton
The Parkinson's Foundation @parkinsondotorg.bsky.social · 23/05/2025
A strong link has been shown between Parkinson's disease and exposure to pesticides and herbicides. Learn more about environmental causes of PD: Parkinson.org/understanding-parkinsons/causes/environmental-factors
parkinson.org
Environmental Factors
Environmental exposures linked to Parkinson's disease that scientists are working to better understand.
031
Reposted by Will Scotton
UCL Faculty of Brain Sciences @uclbrainscience.bsky.social · 21/05/2025
How might AI help us to detect dementia through retinal scans? 👀 We spoke to Professor Pearse Keane (@ucleye.bsky.social) about pioneering studies in the emerging field of #oculomics. ➡️ bit.ly/3XuReOH @moorfieldsbrc.bsky.social #UCLDementia #DementiaActionWeek
Reads: “For more than 100 years, doctors have known that the eyes can be used as a window to the rest of the body. Now, thanks to the power of AI and big data, we can find information hidden within retinal images and use this information to pick up early signs of neurodegenerative diseases.”
033
Reposted by Will Scotton
Selina Wray @selinawray.bsky.social · 15/05/2025
Wow!
032
Reposted by Will Scotton
Dr Anna Volkmer @annavolkmer.bsky.social · 17/04/2025
We are doing a survey to understand why other professionals do/don't refer people with Primary Progressive Aphasia for speech-language support We want Drs, nurses, psychologists, social workers, OTs, PTs & any other profession. The survey can be accessed here: qualtrics.ucl.ac.uk/jfe/form/SV_...
qualtrics.ucl.ac.uk
Qualtrics Survey | Qualtrics Experience Management
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
22126
Reposted by Will Scotton
Marc Aurel Busche @marcaurelbusche.bsky.social · 16/05/2025
Hiring! We're looking for a postdoc to join my lab at the @ukdri.ac.uk @ucl.ac.uk We’re investigating neuronal and circuit dysfunction in Alzheimer's, and developing innovative new treatments. Apply here👇 shorturl.at/LpCAq
shorturl.at
UCL – University College London
UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).
11521
Reposted by Will Scotton
University Health Network @uhn.ca · 09/05/2025
Early results of an Adaptive Deep Brain Stimulation trial show promising improvements in speech, movement and quality of life for patients with #Parkinsons. Learn more through the eyes of patient Fabio Dywer and #TeamUHN neurologist Dr. @alfonsofasano.bsky.social Fasano: bit.ly/3F4bTCB
Dr. Alfonso Fasano, a neurologist at University Health Network in Toronto, talks with Dwyer. (Turgut Yeter/CBC)
094
Reposted by Will Scotton
VIB-KU Leuven Center for Neuroscience @vibneuroleuven.bsky.social · 18/04/2025
🚀 New study reveals how four different anti-amyloid drugs interact with amyloid beta protein. They found that lecanemab performed best in binding to small oligomeric forms of the amyloid protein, suggesting a working model for treating people in the earlier stages of Alzheimer’s (1/4)
122
Reposted by Will Scotton
Art Walaszek, MD @walaszek.art · 24/04/2025
I appreciated learning at the @wisconsinadrc.bsky.social ADRD Research Day about new criteria for limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE has been recently been identified as a fairly common cause of memory loss. alz-journals.onlinelibrary.wiley.com/doi/full/10....
alz-journals.onlinelibrary.wiley.com
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC...
023
Reposted by Will Scotton
ERN-RND @ern-rnd.bsky.social · 24/04/2025
💻 Upcoming #webinar on “Recent Advances in Clinical Trials in Multiple System Atrophy” 📅 20th May, 3:00 CEST 🗣️ David Bendetowicz, University Hospital Bordeaux, France Sign up 👉 t1p.de/ri7k3 Joint with the European Reference Network for Rare Neuromuscular Diseases and @ean.org
032
Reposted by Will Scotton
The Lancet @thelancet.com · 24/04/2025
Genetic mutations contribute to a small but significant portion of Amyotrophic lateral sclerosis (ALS) cases. A new @thelancetneuro.bsky.social Series summarises groundbreaking research on genetic ALS, offering insights into potential treatments: tinyurl.com/544kx3fu
Morphologically distinct TDP-43 aggregates. Representative photomicrographs (mag 40×) from the anterior horn of the cervical spinal cord of patients with amyotrophic lateral sclerosis (as described by Spence et al) and a healthy control individual. Copyright: 2025 Elsevier Ltd. All rights reserved.
05412
Reposted by Will Scotton
Melissa E. Murray @drneurochic.bsky.social · 11/01/2025
With so many great tau researchers like @leatgrinberg.bsky.social @lucbuee.bsky.social @sjorsscheres.bsky.social @selinawray.bsky.social @karchlab.bsky.social on #SciSky could not help but put together my 1st starterpack⤵️ We are all fighting for you @curemaptftd.bsky.social 💙 go.bsky.app/KHno2VG
33212
Reposted by Will Scotton
PacBio @pacbio.bsky.social · 24/04/2025
A first in human genomics: a 4-generation pedigree reference, now in Nature. Built with #PacBio HiFi, it maps de novo mutation rates, reveals paternal bias, and captures high mutation rates in tandem repeats—even in Y and repeat-rich regions. Paper here: go.nature.com/4lGMPlP #TheresHiFiForThat
go.nature.com
Human de novo mutation rates from a four-generation pedigree reference - Nature
Analysis of more than 95% of each diploid human genome of a four-generation, twenty-eight-member family using five complementary short-read and long-read sequencing technologies provides a truth set t...
1106
Reposted by Will Scotton
UCL Faculty of Brain Sciences @uclbrainscience.bsky.social · 13/04/2025
#ICYMI A new AI tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by @uclqsion.bsky.social researchers. buff.ly/bXwvg35
buff.ly
AI tool can track effectiveness of multiple sclerosis treatments
A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers.
011
Reposted by Will Scotton
UCL Queen Square Institute of Neurology @uclqsion.bsky.social · 07/04/2025
Final programme for this event is now available! www.ucl.ac.uk/ion/events/2...
ucl.ac.uk
Inaugural UCL Dystonia Day symposium
The UCL Dystonia Day Symposium seeks to bring basic and clinical researchers together to address this critical question. The Symposium will showcase cutting-edge research from early career researchers...
023
Reposted by Will Scotton
Charles Marshall @charlesmarshall.bsky.social · 19/03/2025
🚨Fantastic job opportunity for neurology trainees Neurology Clinical Lecturer post in Dementia with us @qmuldementia.bsky.social now open to applications! Please DM me for info and to discuss www.oriel.nhs.uk/Web/PermaLin...
oriel.nhs.uk
Oriel
Published vacancies that are available for applicants to apply to. This includes key information suchs as the training programme(s), post type(s), advert information and duration.
034
Reposted by Will Scotton
James Catterson @scotsfriction.bsky.social · 24/03/2025
"In the absence of replication, together with private conversations, such papers used to quietly die. Now they are being publicly murdered. I am not sure which is the better way." - Prof John Hardy www.alzforum.org/papers/bad-m...
alzforum.org
The Bad Medicine of Doctored | ALZFORUM
073
Reposted by Will Scotton
Dementia Researcher @dementiaresearcher.bsky.social · 24/03/2025
Accelerate your MND research from lab to patient! Up to £500k available through My Name’5 Doddie Foundation's 2025 Advancing Treatments Award. #MotorNeuroneDisease @mndoddie5.bsky.social www.dementiaresearcher.nihr.ac.uk/funding/mnd-...
dementiaresearcher.nihr.ac.uk
MND Advancing Treatment Awards - DEMENTIA RESEARCHER
The My Name’5 Doddie Foundation Advancing Treatments Award will support the early-stage development of new treatments to slow, stop or reverse MND progression
054
Reposted by Will Scotton
Dr Anna Volkmer @annavolkmer.bsky.social · 21/03/2025
2-weeks till PPA awareness day 4 April! Webinar link: speechtherapyppa.com/ppa-awarenes... This wk we are sharing another podcast, this time created with student speech & language therapists abt the UCL PPA clinic: podcasts.apple.com/gb/podcast/e... #PPAawareness @ppaphasiaawareness.bsky.social
146
Reposted by Will Scotton
Dementia Researcher @dementiaresearcher.bsky.social · 21/03/2025
Applications are invited for a Group Leader in the @ukdri.ac.uk at the University of Cambridge, Department of Clinical Neurosciences, Cambridge Biomedical Campus. Closing date: 28th April www.dementiaresearcher.nihr.ac.uk/job/ukdri-gr...
dementiaresearcher.nihr.ac.uk
UKDRI Group Leader/ Senior Research Associate
Applications are invited for a Group Leader in the UK Dementia Research Institute at University of Cambridge, Department of Clinical Neurosciences
027
Reposted by Will Scotton
Nico Franzmeier @nfranzme.bsky.social · 18/03/2025
Excited to share our new work in Molecular Neurodegeneration, showing that α-synuclein co-pathology is common in Alzheimer’s and accelerates amyloid-related tau accumulation, supporting its role as a tau co-aggregation factor. doi.org/10.1186/s130...
doi.org
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease - Molecular Neurodegeneration
Background Aggregated alpha-Synuclein (αSyn) is a hallmark pathology in Parkinson’s disease but also one of the most common co-pathologies in Alzheimer’s disease (AD). Preclinical studies suggest that...
1248
Will Scotton @drwillscotton.bsky.social · 15/03/2025
😳😳 onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Unprecedented Combination of Rare Degenerative Pathologies in an Octogenarian Ex‐Football Player
A 79-year-old former professional football player presented with language deficits and cognitive changes. A year later, he had difficulty completing sentences, and 3 years after onset, was reduced to....
000
Reposted by Will Scotton
The BMJ @bmj.com · 12/03/2025
The number of patients entering clinical trials in the UK fell by 27% from 2018 to 2023 and new industry trials declined 38%. To revive clinical research we need to streamline systems and dismantle bureaucracy, writes @masudhusain.bsky.social www.bmj.com/content/388/...
13114
Reposted by Will Scotton
ERN-RND @ern-rnd.bsky.social · 10/03/2025
Register for our WinterSchool with Bernhard Landwehrmeyer, who will be talking about Disease-Modifying Treatment Approaches/Trials in Huntington's Disease on March 12. In collaboration with the European Paediatric Neurology Society. Registration: t1p.de/eajix, Programme: t1p.de/jrxm9
001
Reposted by Will Scotton
The Neurogenetics Lab ION @qs-neurogenetics.bsky.social · 09/03/2025
At MSA Health & Care Professionals Study Day, Prof Henry Houlden provided an overview of MSA offering key insights for healthcare professionals. Dr Yee Yen Goh presented on how to diagnose MSA in patients, outlining key clinical markers & diagnostic approaches. @uclqsion.bsky.social
022
Reposted by Will Scotton
Jonathan Schott @jmschott.bsky.social · 06/03/2025
10th annual @uclqsion.bsky.social neurology course — book your place now www.ucl.ac.uk/ion/neurolog...
ucl.ac.uk
Neurology 2025: leading edge neurology for the practising clinician
023
Reposted by Will Scotton
Eduardo Argüelles-González @eddargo.bsky.social · 24/02/2025
Neuroimaging Techniques in #Huntington's Disease: A Critical Review 🧠 #Neurology #movedisorder #MedEd movementdisorders.onlinelibrary.wiley.com/doi/10.1002/...
movementdisorders.onlinelibrary.wiley.com
Neuroimaging Techniques in Huntington's Disease: A Critical Review
Background Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by cognitive, neuropsychiatric and motor symptoms caused by a CAG trinucleotide repeat expansion in the ...
032
Reposted by Will Scotton
Dementia Researcher @dementiaresearcher.bsky.social · 25/02/2025
Omega-3 fatty acids—found in fish, nuts & seeds—have been linked to slower #MND progression. New research from @ukdri.ac.uk shows why: boosting these fats in brain cells improves survival! Next step? Testing in humans. 🔗 #ALS #FTD #plantbased buff.ly/3D0o1Uh
1115
Reposted by Will Scotton
Jonathan Schott @jmschott.bsky.social · 12/02/2025
Latest *open access* paper — with @ProfHampshire we evaluated the @iamcognitron remote cognitive battery in the @MRCLHA 1946 birth cohort and explored relationships with biomarkers alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
032
Will Scotton @drwillscotton.bsky.social · 12/02/2025
academic.oup.com/braincomms/a... delighted to finally see this out. We asked the question - could we identify different subtypes of CBS using SuStaIn algorithm applied to a baseline structural MRI scan and if so did these associate with underlying pathology? Read the paper to find out!
academic.oup.com
Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologies
Scotton et al. report distinct subtypes of atrophy progression in corticobasal syndrome identified using machine learning analysis of structural MRI scans.
072
Reposted by Will Scotton
Brain @brain1878.bsky.social · 10/02/2025
Wiseman et al. provide evidence that the rapid neurodegeneration observed in MSA is driven by toxic α-synuclein fibrils invading neuronal nuclei. They propose redefining MSA as a neuronal nuclear and oligodendroglial α-synucleinopathy. buff.ly/3EGnUxo
011
Reposted by Will Scotton
Brain @brain1878.bsky.social · 10/02/2025
Liu et al. analyse APP, PSEN1, and PSEN2 variants associated with autosomal dominant AD, focusing on symptomatic age at onset (AAO) for each mutation and whether AAO in carriers can be predicted based on mean variant AAO and parental AAO. buff.ly/42Oo93t
021
Reposted by Will Scotton
Dr Aida Suarez Gonzalez @aidasuarez.bsky.social · 06/02/2025
🚀 The Rare Dementia Support Centre opens in autumn 2025, launching a new era in post-diagnostic care for: 🔹 PCA 🔹 PPA 🔹 FTD 🔹 LBD 🔹 Familial Dementias Can´t wait to help make this place thrive. Watch this space for updates 👀 @uclbrainscience.bsky.social @ucl.ac.uk #RDSC: bit.ly/4hKYVrb
bit.ly
Rare Dementia Support Centre Appeal - The National Brain Appeal
Help us fund the world's first Rare Dementia Support Centre. The centre will exemplify how best to support those living with a rare form of dementia.
096
Reposted by Will Scotton
Paresh Malhotra @pareshmalhotra.bsky.social · 10/01/2025
JOB ALERT FOR NEUROLOGY TRAINEES. On www.oriel.nhs.uk now. Academic Clinical Lecturer post in Dementia & Neurodegeneration @imperialbrains.bsky.social. Research can cover any aspect of the above. Please repost and feel free to contact me if interested (am at ABN SIG meeting today).
01113
Reposted by Will Scotton
The Lancet Neurology @thelancetneuro.bsky.social · 05/02/2025
New in The Lancet, a phase 3 randomised trial of exenatide for Parkinson's disease showed no evidence to support this GLP-1 receptor agonist as a disease-modifying treatment @thelancet.bsky.social #neurosky #medsky www.thelancet.com/journals/lan...
thelancet.com
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo...
Our findings suggest that exenatide is safe and well tolerated. We found no evidence to support exenatide as a disease-modifying treatment for people with Parkinson's disease. Studies with agents that...
0179
Reposted by Will Scotton
Jonathan Schott @jmschott.bsky.social · 07/02/2025
New *open access* paper in @alzdemjournals — with the @alzassociation #GBSC we compared 33 different plasma p-tau assays. TLDR — Plasma p-tau217 on several platforms was the best at discriminating Alzheimer’s from controls alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
alz-journals.onlinelibrary.wiley.com
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study
INTRODUCTION The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-...
042
Reposted by Will Scotton
Mike Greicius @mikegreicius.bsky.social · 31/01/2025
Excited to be chairing a new Stanford faculty search in Neurology. We are looking for MD and MD/PhD physician-scientists who have a strong research program (wet lab or dry lab) and who are also excellent clinicians. Please spread the word. Here's the link to the job posting: lnkd.in/d6REUGfM
0117